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Abstract
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related deaths worldwide. HCC initiates
as a consequence of chronic liver damage and inflammation caused by hepatitis B and C virus infections,
excessive alcohol consumption, or non-alcoholic fatty liver disease (NAFLD). Until recently, no effective treat-
ments for advanced HCC were available and the 5-year survival rate had remained below 8% for many years.
New insights into the mechanisms that drive the development of NAFLD-related HCC indicate that loss of
T-cell-mediated immunosurveillance plays a cardinal role in tumor growth and malignant progression, in
addition to previously identified inflammation-driven compensatory proliferation. Recently completed
groundbreaking clinical studies have shown that treatments that restore antitumor immunity represent a
highly effective therapeutic option for approximately 20% of advanced HCC patients. Understanding the
causes of inflammation-driven immunosuppression and immune system dysfunction in the 80% of patients
who fail to reignite antitumor immunity despite treatment with checkpoint inhibitors should lead to further
and even more dramatic improvements in HCC immunotherapy.
Introduction
Hepatocellular carcinoma (HCC) is the most common
form of liver cancer and second leading cause of cancer-
related deaths worldwide.1 Despite a general decline in
cancer-related deaths, HCC incidence in the USA and its
associated mortality continue to grow at an alarming
rate, with a tripling of HCC-related mortality in the past
30 years.2 Historically, the main causes of HCC were
hepatitis B and C virus (HBV, HCV) infections, but the
incidence of virus-related HCC is predicted to decline
within the next generation because of development of
effective and economical HBV vaccines and the recent
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introduction of highly effective anti-HCV drugs.1,3 By
contrast, the incidence of non-viral hepatitis continues
to rise and it is already a leading cause of cryptogenic
cirrhosis and liver transplantation in the USA and
Europe.4,5 Major causes of non-viral hepatitis include
the obesity epidemic, which has greatly increased the
incidence of non-alcoholic fatty liver disease (NAFLD),
and rampant alcohol abuse, which results in alcoholic
liver disease (ALD).6 Surgical resection and liver trans-
plantation represent effective treatment options for
early, localized HCC, but unfortunately the majority of
HCC cases are diagnosed at a rather advanced stage,
and are frequently associated with loss of liver function.
Compromised liver function means that advanced HCC
cannot be treated with high doses of chemotherapy or
ionizing radiation and the only evidence-based targeted
therapeutic approved for first-line HCC treatment is the
pan-kinase inhibitor sorafenib, which extends life by
less than 3 months without an impact on 5-year sur-
vival rates, which have persisted at <8% for stage 4
patients.7 Furthermore, sorafenib is a highly hepato-
toxic drug that is not suitable for all patients.
Until recently, the only meaningful improvements in
HCC treatment have been: 1) the establishment of strict
criteria for performance of liver resection and liver
transplantation,8,9 and 2) patient classification and
stratification, which help identify those who will benefit
most from first-line sorafenib treatment.10,11 This lack
of progress in HCC treatment is most likely because of
the absence of reliable biomarkers that allow for effect-
ive screening of high-risk patients and early disease
detection. This poor state of affairs is likely to change.
Recent clinical studies have demonstrated that single-
agent treatment with immune checkpoint inhibitors
such as nivolumab and pembrolizumab, antibodies that
block engagement of the inhibitory receptor PD-1, which
is expressed by exhausted CD8+ T cells, led to a signifi-
cant decrease in tumor burden in ~20% of advanced
HCC patients.12,13 These findings are entirely consistent
with the results of a recent preclinical study which
showed that loss of T-cell-mediated immunosurveil-
lance from inflammation-driven immunosuppression
plays a cardinal role in the development of NAFLD-
associated HCC.14 This incredible and rare convergence
between mechanistic preclinical research and empirical
clinical investigation strongly suggests that immuno-
therapies aimed at restoring HCC immunosurveillance
will revolutionize the treatment of this highly aggres-
sive malignancy and may also lead to its prevention in
high-risk individuals.
Preclinical models for understanding HCC
etiology and pathogenesis
Currently, the majority of HCC cases in the USA and
Europe are caused by HCV hepatitis, non-alcoholic stea-
tohepatitis (NASH), or alcoholic steatohepatitis (ASH).1
However, in the not-too-distant future, the prevalent
HCC etiologies in Western society are predicted to be
associated with non-viral hepatitides (especially NASH
and ASH), that are driven by the ever-expanding obesity
epidemic4 and excessive alcohol consumption. HBV- or
HCV-induced HCC has been difficult to study in mice,
because these viruses do not replicate in non-primate
mammals. Early attempts to study HBV- and HCV-
induced HCC in mice were based on transgenic expres-
sion of whole virus genomes or parts of them from
liver-specific promoters.15–18 Although HBV and HCV
transgenic mice develop HCC after a considerable
latency, it is questionable whether the tumorigenic
mechanisms operating in these mice are related to
those that function in HBV- or HCV-infected humans.
While HBV is a DNA tumor virus that is thought to
induce HCC through insertional mutagenesis,19 HCV is a
non-integrating RNA virus that does not code for any
oncogene.20 It has been speculated that HCV replication
within hepatocytes causes endoplasmic reticulum (ER)
stress that leads to induction of hepatic steatosis,
chronic liver damage, and inflammation, outcomes that
have also been detected in HCV transgenic mice.21,22
Curiously, ER stress was also suggested to be asso-
ciated with the most severe manifestation of NAFLD—
NASH23–26—suggesting that HCV infection and NASH
may lead to HCC development through a common
pathogenic mechanism that involves ER stress. To
determine whether hepatocyte ER stress can contribute
to HCC development, we chose to use MUP-uPA trans-
genic mice, which express urokinase plasminogen acti-
vator (uPA) from the liver-specific major urinary protein
(MUP) promoter.26 By exceeding the folding and secre-
tory capacity of hepatocytes in the newborn liver, uPA
expression results in ER stress and transient liver dam-
age that subsides after 6 weeks of age because of trans-
gene extinction.26,27 By placing 6-week-old MUP-uPA
mice on a high-fat diet (HFD), we were able to reignite
the ER stress response and cause activation of sterol
response element binding proteins (SREBP), thereby
enhancing the accumulation of liver triglycerides (TG)
and cholesterol within hepatocytes.28,29 Whereas TG
accumulation leads to simple hepatic steatosis, the
buildup of free, unesterified cholesterol acts in conjunc-
tion with TNF, which is produced by activated liver
macrophages,29 to amplify the extent of liver inflamma-
tion and damage. Thus, both free cholesterol and TNF
serve as critical factors in controlling the transition
from hepatic steatosis or early NAFLD to NASH in both
mice and humans.30–33 Indeed, within several months
of HFD initiation, MUP-uPA mice develop extensive liver
inflammation manifested by massive leukocytic infiltra-
tion, chronic liver damage, and hepatocyte death, which
result in compensatory proliferation, a “chicken-wire”
pattern of fibrosis, and accumulation of Mallory-Denk
Bodies (MDB), which are inclusion bodies composed of
p62-containing protein aggregates. Of note, MDB serve
22 | Michael Karin
as a typical sign of chronic liver diseases associated
with increased risk of HCC development,29,34 but as dis-
cussed below, their main constituent, p62, is also a
cause of hepatic tumorigenesis. All of these responses
are characteristic of human NASH24 and are entirely
dependent on TNF signaling via the type I TNF receptor
(TNFR1) that is expressed on the surface of hepatocytes.
Genetic ablation of TNFR1 or TNF titration using Enbrel
(etanercept) completely prevents NASH development in
HFD-fed MUP-uPA mice.29 Anecdotal clinical reports
indicate that Enbrel or Remicade (infliximab) treatment
lead to improvement of NASH symptoms in both ani-
mal models and human patients,35–38 although this
should be contrasted with the failure of such drugs in
alcoholic hepatitis.18 It should be noted, however, that
ASH patients are much more likely to develop severe
infections than NASH patients, thereby precluding the
use of anti-TNF drugs, which otherwise had shown
promising results.39 Importantly, within 9 months of
HFD initiation, at least 85% of HFD-fed MUP-uPA male
mice (HCC is much more common in males than in
females40) show numerous, poorly differentiated HCC
nodules with about 50% of them having the appearance
of steatotic HCC.29
Consistent with early results published by the
Pikarsky group,41 TNFR1 signaling via IκB kinase β (IKKβ)
also plays an important role in NASH to HCC progres-
sion by stimulating the proliferation of HCC progenitor
cells (HcPC).29 Another important player in NASH to
HCC progression is p62/SQSTM1. Hepatocyte-specific
ablation of the Sqstm1 gene largely attenuates HCC
development in HFD-fed MUP-uPA mice.34 In addition to
its propensity for forming protein aggregates, MDB, and
hyaline granules,42 p62 is an important signaling
protein43 whose tumorigenic activity is exerted via acti-
vation of transcription factor NRF2. A point mutation in
the KIR motif of p62, which prevents its binding to
KEAP1, the negative regulator of NRF2,44 also blocks the
ability of overexpressed p62 to induce HCC develop-
ment.34 p62-mediated NRF2 activation also plays an
important role in the development of pancreatic cancer,
stimulating the malignant progression of preneoplastic
PanIN1 lesions.45 Gain-of-function mutations in the
NRF2-encoding NFE2L2 gene and loss-of-function muta-
tions in the KEAP1 gene, both of which lead to constitu-
tive NRF2 activation, were detected in up to 12% of
human HCC specimens.46,47
In addition to sharing identical pathological features
and common oncogenic signaling pathways, HCCs that
have appeared in MUP-uPA mice are essentially identi-
cal to human HCC in their mutational signature, which
exhibited a marked enrichment for C to T transitions.14
The mutational load of mouse NASH-driven HCC is also
quite similar to that of human HCC, averaging 50–100
coding region point mutations per tumor. Many of these
mutations affect oncogenic drivers that were first
detected in human HCC.14,46,47
The oncogenic role of inflammation-
driven immunosuppression
Another important feature of both NASH and ASH that is
closely associated with liver fibrosis is the presence of
high amounts of circulating immunoglobulin A (IgA).48,49
In both NASH and ASH, the serum concentration of IgA
is directly proportional to the extent of liver fibrosis.48
HFD-fed MUP-uPA mice and other mouse models of liver
fibrosis or NASH exhibit a positive correlation between
circulating IgA and liver fibrosis.14 Circulating IgA in
NASH-afflicted mice is produced by liver-infiltrating plas-
ma cells that have undergone IgM to IgA class switch
recombination (CSR) in response to TGF-β and other cyto-
kines, such as IL-21 and IL-33, whose expression is ele-
vated in response to chronic liver inflammation.14 Using
freshly collected liver biopsies, we confirmed the pres-
ence of liver-infiltrating IgA-expressing plasma cells in
human NASH and have shown that these cells, as well
as their progenitors, IgA+ plasmablasts, also express the
inhibitory ligand PD-L1 and the immunosuppressive
cytokine IL-10.14 Using the MUP-uPA + HFD model we
have developed, we demonstrated that these cells, col-
lectively referred to as immunosuppressive plasmocytes
(ISPs), are the principal source of PD-L1 in NASH-driven
HCC and are directly responsible for inducing the
exhaustion of HCC-directed CD8+ T cells.14 Ablation of
the IgA locus or inhibition of ISP generation through
interference with TGF-β signaling resulted in attenuation
of HCC development and concomitant reinvigoration of
HCC-directed cytotoxic T cells (CTLs). Depletion of CTLs
using a CD8 neutralizing antibody restored NASH-
induced HCC development in IgA-deficient mice.14 A
dramatically reduced tumor load was observed after
treatment of HCC-bearing MUP-uPA mice with a PD-L1
blocking antibody, but the few tumors that did develop
in ISP-deficient mice were completely refractory to PD-L1
blockade.14 These results indicate that IgA+ ISP, which
accumulate in response to chronic liver damage, inflam-
mation, and fibrosis, are the most critical source of PD-L1
in HCC, a tumor whose development is strongly depend-
ent on the suppression of CTL-mediated immunosurveil-
lance. In support of these conclusions, HCC development
is highly accelerated in MUP-uPA/Cd8a−/− mice, which
lack CTL.14 HCC development is also accelerated in MUP-
uPA/Rag1−/− mice, whose reconstitution with T cells in
the absence of B cells inhibits tumor development. We
conclude that HCC-directed liver-infiltrating CD8+ T cells
are potent inhibitors of HCC emergence because of their
ability to recognize and kill HCC progenitors. These find-
ings are summarized in Fig. 1.
The PD-1 checkpoint and the therapeutic
effect of its inhibition
PD-L1 is the main ligand for the inhibitory receptor PD-1
(programmed death-1). PD-1 is expressed by CD8+
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cytotoxic T cells as well as CD4+ T follicular helper cells
(Tfh), whereas PD-L1 can be expressed by many different
cell types, including macrophages, B cells, and epithelial
cells.50,51 The engagement of PD-1 on the surface of CD8+
T cells inhibits their proliferation and all of their effector
functions, thereby resulting in a dysfunctional state that
is commonly referred to as exhaustion.52,53 Importantly,
this inhibitory response is needed to prevent the rampant
activation of antiviral CTLs, and its absence can result in
severe collateral damage and even mortality in response
to viral infections.54 In fact, myeloid and epithelial cells
begin to express PD-L1 in response to interferon γ (IFN-γ)
that is produced by activated CTLs, thereby constituting a
negative feedback loop. Engagement of PD-1 on the sur-
face of Tfh cells also inhibits cell proliferation but it also
leads to induction of IL-21 and other molecules through
which Tfh stimulate the maturation of plasma cells,
including IgA-expressing plasma cells55,56 (Fig. 1).
In addition to the control of antiviral immunity and
Tfh function, it was found that PD-1:PD-L1 interactions
play a cardinal role in antitumor immunity. Many types
of cancer express PD-L1 on their surface and thereby
lead to the exhaustion of tumor-directed CTL.57,58
Consistent with these observations, it was found that
treatment of tumor-bearing mice with antibodies
against either PD-1 or PD-L1 that block the interaction
between the two molecules triggers tumor regression
and concomitant reactivation/reinvigoration of tumor-
directed CD8+ T cells.59,60 These impressive preclinical
results and the success of blocking antibodies directed
against another T-cell checkpoint regulator CTLA461
quickly led to clinical trials of the first fully human PD-1
blocking antibody, nivolumab, which resulted in an
objective response rate (ORR) of 17% in non-small cell
lung cancer.62,63 Since then, nivolumab, pembrolizumab,
and the PD-L1 antagonistic antibody atezolizumab, have
received approvals for the treatment of melanoma, lung
cancer, bladder cancer, kidney cancer, head and neck
cancer, and Hodgkin lymphoma.50,64 It was initially pos-
tulated that only cancers with high mutational load can
be treated with checkpoint inhibitor drugs, including
PD-L1 inhibitors,63,65,66 but this short-lived dogma has
not prevented oncologists from testing these drugs in
cancers with lower mutational loads, such as renal cell
carcinoma67 and HCC.12 Surprisingly, the response rates
to all PD-1:PD-L1 inhibitors were found to cluster around
15–25% and do not seem proportional to the total num-
ber of mutations a particular tumor harbors.50 Clearly,
mutational load is not the only factor that affects the
response to checkpoint inhibitors. Another factor sug-
gested to affect the response to PD-1:PD-L1 interaction
inhibitors is the level of PD-L1 expression on tumor
cells.50,62 Although PD-L1 expression is needed for acti-
vation of the PD-1 checkpoint and to make the involved
tumor responsive to PD-1:PD-L1 inhibitors, the degree of
PD-L1 expression by cancer cells themselves was not
found to directly correlate with response rates. Further-
more, the source of PD-L1 is highly variable and many
cancers show PD-L1 expression by components of the
tumor microenvironment, rather than the malignant
cells themselves.68,69 Correlating PD-L1 expression with
response rates to PD-1:PD-L1 antagonists has not been
highly reliable because of the mediocre quality of the
reagents and methodology used to assess PD-L1 expres-
sion. Given that in non-viral HCC the most critical
source of PD-L1 are the IgA+ ISP,14 it is not surprising
that no correlation was found between the response to
nivolumab and PD-L1 expression on HCC cells.12 We
postulate that the presence of elevated serum IgA and
liver-infiltrating IgA+ ISP can be a much more accurate
parameter for predicting responsiveness to PD-1/PD-L1
targeting agents in human HCC. Elevated circulating IgA
has also been detected in HBV- and HCV-infected
patients70–73 and is much easier to measure than to
quantitate PD-L1 expression in tissue/tumor sections.
PD-1:PD-L1 blockade: a revolution in HCC
treatment
As mentioned above, PD-1/PD-L1 blocking therapies
were thought to be irrelevant for the treatment of HCC
because the typical HCC mutational load is lower than
the cutoff value postulated to be needed for anti-PD-1/
PD-L1 responsiveness.63,66 Furthermore, hepatitis is a
common side effect of checkpoint inhibitor therapy74,75
and it was therefore assumed that advanced HCC
patients would not be able to tolerate such a complica-
tion. These considerations, however, did not prevent El-
Khoueiry and colleagues from conducting the CheckMate
Figure 1. Key molecular elements that dictate the balance between
tumor immunity and inflammation-driven immunosuppression.
Tfh, follicular helper T cells; ISP, immunosuppressive plasmocytes.
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040 trial, the first clinical study that clearly demonstrated
the effectiveness of nivolumab monotherapy in advanced
HCC.12 The phase 1/2 CheckMate 040 clinical study enrolled
262 patients with histologically confirmed advanced HCC,
including patients with non-viral HCC, HCV-infected, and
HBV-infected patients. Of these groups, patients with
non-viral hepatitis or HCV hepatitis were observed to
exhibit an ORR of 20–25%, whereas HBV-infected patients
exhibited an ORR of 14%.12 Although the study was insuf-
ficiently powered to correlate response rates with eti-
ology, the results suggest that HBV-infected patients are
actually less responsive to PD-1 blockade therapy than
non-virus-infected patients or HCV-infected patients.
This is somewhat counterintuitive because HBV infection
should result in expression of viral antigens that are
potent T-cell activators. Of note, the CheckMate 040 study
found no correlation whatsoever between membrane
expression of PD-L1 by HCC cells and the response to PD-
1 blockade,12 further demonstrating the weakness of the
hypothesis according to which the response to anti-PD-1
drugs is determined by PD-L1 expression on the surface
of cancer cells. The clinical findings reported by El-Khoueiry
et al. are fully consistent with the finding of our preclinical
study of NASH-driven HCC and its control by the inter-
action between IgA+ ISP and CD8+ CTLs.14 The mouse
studies demonstrated that PD-L1 mediated exhaustion of
HCC-targeting CD8+ T cells plays a critical role in HCC
development, therefore suggesting that the PD-1 check-
point is key to HCC development. Despite low PD-L1
expression by HCC cells, the use of nivolumab resulted in
disease control in 67% of patients with non-viral HCC or
HCV-related HCC and 55% of patients with HBV-related
HCC. These striking results should be compared with
response rates of 2–3% in HCC patients treated with first-
line sorafenib.76,77 The median duration of the response
to nivolumab was as high as 17 months in the dose-
escalation phase of the trial,12 far exceeding the 3-month
extension in survival offered by sorafenib. Even the early
fear of nivolumab-induced hepatitis has not panned out.
Only two patients out of 202 who completed the trial experi-
enced acute hepatitis and the overall rate of adverse
events was not any higher than in any other population
of similarly treated cancer patients. Thus, there is no
question that anti-PD-1/PD-L1 therapies will become the
game-changers that will revolutionize HCC treatment.
Shortly after completion of the CheckMate 040 trial, nivo-
lumab was approved for the treatment of advanced HCC
when used following prior treatment with sorafenib.
Hopefully, future studies will show nivolumab, pembroli-
zumab, and similar drugs are suitable for first-line HCC
treatment without prior administration of sorafenib, which
has no effect on the rate or duration of the therapeutic
response.12 Similar and more extensive responses were
seen in HCC-bearing MUP-uPA mice that were treated
with a PD-L1 blocking antibody.14 We initiated anti-PD-L1
treatment after 7 months of HFD feeding, a time point at
which the majority ofMUP-uPAmice exhibit visibly detect-
able liver tumors. After 8 weeks of 3 injections per week
with two different PD-L1 antibodies, only one of which is
a functional blocking antibody, we observed that PD-L1
blockade led to 60% reduction in tumor load relative to
control.14 The therapeutic effect of PD-L1 blockade was
most noticeable on larger tumors, most of which had
disappeared. In addition to demonstrating the utility of
PD-L1 blockade in a mouse model that is amenable to
detailed mechanistic analysis, this experiment has taught
us several very important lessons. First, tumor-bearing
mice that lack PD-L1-expressing ISP did not show any
response to PD-L1 blockade, indicating that in NASH-
driven HCC, at least in mice, the critical functional source
of PD-L1 are the ISP. Although HCC tumor cells express
small amounts of PD-L1, that particular PD-L1 is not func-
tionally important. These results are entirely consistent
with those of the CheckMate 040 trial. Second, tumors in
MUP-uPA/Cd8a−/− mice also did not respond to anti-PD-L1
treatment, indicating that the targets for PD-1/PD-L1
blockade are the exhausted CD8+ T cells. Indeed, anti-PD-
L1 treatment of wildtype MUP-uPA mice decreased the
liver content of exhausted CD8+ T cells and increased the
number of proliferating and degranulating effector CD8+
T cells that express TNF, IFN-γ, granzyme B, and
perforin.14 These results indicate that CD8+ T cells not
only prevent HCC initiation through immunosurveillance,
but also that they are responsible for the rejection of
established tumors in response to treatment with PD-1:
PD-L1 blocking antibodies. In other words, tumors that do
not contain exhausted CD8+ T cells are unlikely to be
responsive to PD-1/PD-L1 blockade.
The preclinical mouse studies may have also pro-
vided us with a precious clue that could explain why no
more than 25% of HCC patients mount a response to
nivolumab treatment. We observed that the few HCC-
bearing mice that did not show a response to PD-L1
blockade contained tumors that were surrounded by an
envelope of activated hepatic stellate cells (HSC), the
kind of cells that are responsible for extracellular matrix
deposition during liver fibrosis.14 In addition to the
envelope of activated HSC, these tumors contained very
few infiltrating T cells and most of the reinvigorated
CD8+ effector T cells stayed outside of the tumor. In this
respect, these treatment refractory tumors resembled
pancreatic cancer, which contains an extensive stroma
of activated pancreatic stellate cells and is devoid of
invading CD8+ T cells.78 Of note, we found that similar
to HCC, both mouse and human pancreatic adenocar-
cinomas contain PD-L1-expressing IgA+ plasmocytes.
The significance of these findings remains to be deter-
mined, but they suggest that somehow HSC or pancre-
atic stellate cells interfere with the activation of CTL or
their ability to penetrate the tumor and recognize their
target.
Conclusions and future directions
The rare confluence of preclinical and clinical studies
described above strongly establishes the relevance of
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antitumor immunity to the development and treatment
of HCC, one of the most common and difficult-to-treat
malignancies. It has been known for many years that
HCC development is dependent on chronic liver damage
and inflammation, but until now it was assumed that
the main pro-tumorigenic effect of liver damage is com-
pensatory proliferation, a biological response that sti-
mulates the division of transformed hepatocytes.79,80
The new studies reviewed above indicate that another
important effect of chronic liver damage and the ensu-
ing inflammatory response is the suppression of CTL-
mediated immunosurveillance. As long as it is left
unperturbed, immunosurveillance provides very strong
protection against the growth of nascent HCC lesions,
which emerge from mutated pericentral hepatocytes.81
Given the key pro-tumorigenic effect of inflammation-
driven immunosuppression, a process that depends on
accumulation of PD-L1 expressing ISP, it is no wonder
that drugs that block the binding of PD-L1 to PD-1 and
restore CTL-mediated antitumor immunity are so
remarkably effective in the treatment of advanced HCC.
Despite the incredible clinical advance in HCC treat-
ment represented by PD-1:PD-L1 interaction inhibitors,
the average objective response to this class of drugs is
approximately 20%.12 Undoubtedly, this rate needs to be
increased, but how can this by accomplished? I suggest
that, first and foremost, we need to understand the fac-
tors that render the remaining 80% of HCC patients
non-responsive to PD-1/PD-L1 blockade. Given the depend-
ence of the response to PD-L1 blockade on the presence of
IgA+ ISP,14 it is plausible that some of the non-responsive
patients may have low amounts of liver- and HCC-resident
ISP. As circulating IgA is easy to measure and known to
directly correlate with liver IgA,14 one simple study that
needs to be carried out in the very near future is a correla-
tive study between serum IgA and the response to PD-1/
PD-L1 blockade. It is also important to determine how
many of the non-responsive patients exhibit excessive
accumulation of activated HSC around their tumors and
defective tumoral invasion of reinvigorated CD8+ T cells.
If the findings made in mice are validated in a significant
portion of the anti-PD-1 non-responsive patient popula-
tion, it will become important to test the effect of clinic-
ally approved drugs that are capable of inhibiting HSC
activation. At this point two classes of such drugs come
to mind: 1) phosphodiesterase 5 (PDE5) inhibitors, and 2)
vitamin D analogs. PDE5 inhibitors, such as tadalafil
(Cialis) and sildenafil (Viagra), were previously observed
to inhibit HSC activation and prevent the accumulation of
prostate and lung myofibroblasts, which are highly simi-
lar in their properties to activated HSC.82,83 In fact, tadala-
fil has been approved for the treatment of benign prostatic
hyperplasia and pulmonary hypertension, two diseases
that depend on myofibroblast activation.84,85 Likewise,
the vitamin D analog calcipotriol was found to attenuate
HSC activation and interfere with their ability to express
numerous chemokines and other molecules,86,87 includ-
ing CXCL13, a B-cell chemoattractant, that may account
for the immunosuppressive activity of HSC and other
types of myofibroblasts. Importantly, drugs in both groups
are safe and free of side effects that could reduce the
effectiveness of PD-1/PD-L1 targeting drugs. Another
important line of future research pertains to the involve-
ment of other checkpoint inhibitors, such as antibodies to
TIM-3, LAG-3, and CTLA4, in controlling the immune
response to HCC. So far such studies have not been
reported, but it is plausible that blockade of additional
inhibitory receptors may result in more sustained reinvig-
oration of tumor-directed CD8+ T cells than has been
seen with PD-1 blockade alone.88
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